Du är här

2015-09-08

Swedish Orphan Biovitrum AB (publ): Sobi opens European and Benelux office in Brussels

Today Sobi (Swedish Orphan BiovitrumAB (publ)) formally opened its new
European and Benelux office in Brussels, Belgium. The inauguration,
celebrated today with a ribbon-cutting ceremony, results from Sobi's
expanding international presence and further strengthens the company's
platform in Europe as well as in the Benelux Region.

"Brussels provides an ideal location for our European operations", said Hege
Hellstrom, President EMENAR at Sobi. "Being a company dedicated to rare
diseases, Brussels is of vital importance to Sobi from a business,
regulatory, policy and stakeholder interaction perspective. The Belgian
authorities have also consistently been thought leaders in collaborative,
cross-border approaches to access and availability of rare disease therapies
for patients."

The Brussels office will act as an operational hub for Sobi's business and is
consistent with the strategic importance of Europe for Sobi, representing
approximately 60 per cent of the company's global annual product sales. The
office will also enable additional focus on the business in the Benelux
region.

The opening of the new office in Brussels is a next step in Sobi's mission to
develop and deliver innovative therapies and services to improve the lives of
patients living with rare diseases. With more than 600 employees and offices
in 24 different countries, Sobi currently delivers therapies to patients in
67 countries across the globe. The product portfolio is primarily focused on
Haemophilia, Inflammation and Genetic diseases, and two of the company's
Haemophilia treatments in development are currently being reviewed by the
European Medicines Agency.

- - -

About Sobi
Sobi is an international specialty healthcare company dedicated to rare
diseases. Our mission is to develop and deliver innovative therapies and
services to improve the lives of patients. The product portfolio is primarily
focused on Haemophilia, Inflammation and Genetic diseases. We also market a
portfolio of specialty and rare disease products for partner companies across
Europe, the Middle East, North Africa and Russia. Sobi is a pioneer in
biotechnology with world-class capabilities in protein biochemistry and
biologics manufacturing. In 2014, Sobi had total revenues of SEK 2.6 billion
(€265 M) and about 600 employees. The share (STO: SOBI) is listed on NASDAQ
OMX Stockholm. More information is available atwww.sobi.com.

For more information please contact:

Corporate media relations

Oskar Bosson, Head of Communications

T:+46 704 107 180
oskar.bosson@sobi.com

Regional Contact
Hege Hellstrom, President EMENAR
T: +32 473 888 488
hege.hellstrom@sobi.com

Country Contact
Karel Fol, Country Manager Benelux
T: +32 475 555 775
Karel.fol@sobi.com

032e_new Brussels office
http://hugin.info/134557/R/1950301/709036.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Swedish Orphan Biovitrum AB (publ) via Globenewswire

HUG#1950301

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.